Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Everolimus, Exemestane, Metformin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 102
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more

Conditions: Breast Cancer
Interventions: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 176
States / cities: Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 139 more

Conditions: Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions: Entinostat; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
Interventions: Abemaciclib, Tamoxifen, Anastrozole, Letrozole, Exemestane, LHRH Agonist; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Stamford, Connecticut • Brewer, Maine • Scarborough, Maine + 7 more

Conditions: Breast Cancer
Interventions: core needle biopsy, blood draw; Procedure · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: BIIB021, exemestane (Aromasin); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 19
States / cities: Alabaster, Alabama • Encinitas, California • Gilroy, California + 15 more

Conditions: Breast Cancer
Interventions: Ribociclib, Adjuvant endocrine therapy, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more

Conditions: Breast Cancer
Interventions: ribociclib (LEE011), Exemestane, Everolimus (RAD001); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 8
States / cities: Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more

Conditions: Breast Cancer
Interventions: Everolimus, Exemestane, Everolimus Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 63
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 54 more

Conditions: Solid Tumors and Lymphomas
Interventions: Alobresib, Exemestane, Fulvestrant; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more

Conditions: Poly Cystic Ovary Syndrome
Interventions: Exemestane 25 MG, Placebo, Exemestane 50 MG; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Advanced or Metastatic Breast Cancer
Interventions: PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Irvine, California • Los Angeles, California • Newport Beach, California + 3 more

Conditions: Breast Cancer
Interventions: TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets, Exemestane Tablets; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Greenbrae, California • Parker, Colorado • Chicago, Illinois + 14 more

Conditions: Breast Cancer
Interventions: Sapanisertib, Fulvestrant, Exemestane; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more

Conditions: Metastatic Breast Cancer
Interventions: Belzutifan, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more

Conditions: Metastatic ER+ Her2- Breast Cancer, Postmenopausal
Interventions: Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 24
States / cities: Muscle Shoals, Alabama • Fresno, California • Los Angeles, California + 21 more

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more

Conditions: Neoplasms, Breast
Interventions: Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs); Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Mobile, Alabama • Boston, Massachusetts • Houston, Texas

Conditions: Breast Cancer
Interventions: Enzalutamide, exemestane, Placebo (for enzalutamide); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 89
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more

Conditions: Breast Cancer
Interventions: Exemestane, Avandamet; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Exemestane-RAD001-Metformin

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

The Impact of Obesity and Obesity Treatments on Breast Cancer